PDF Version

PDF 版本

RNS Number : 5093O

RNS编号：5093O

PureTech Health PLC

纯科技健康有限公司

26 June 2025

2025年6月26日

26 June 2025

2025年6月26日

PureTech Health plc

纯科技健康有限公司

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and

PureTech创立的实体Vor Bio宣布与RemeGen达成针对晚期自身免疫资产的全球独家许可协议和

$175 Million

1.75亿美元

Private Placement

私募Placement

PureTech Health plc

纯技术健康股份有限公司

(Nasdaq: PRTC, LSE: PRTC) ('

（纳斯达克：PRTC，伦敦证券交易所：PRTC）（'

PureTech

纯技术

' or the 'Company'),

‘或’公司‘），

a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its

一家处于临床阶段的生物治疗公司，致力于改变患有严重疾病患者的生活，指出其

Founded Entity,

成立实体，

Vor Bio

生物课前

(Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331)

(Nasdaq: VOR)，一家处于临床阶段的生物技术公司，正在改变自身免疫性疾病的治疗方法，以及荣昌生物制药（HKEX: 9995, SHA: 688331）

announced entry into an exclusive license agreement granting

宣布达成一项独家许可协议，授予

Vor Bio

生物课前

global rights (excluding

全球权利（不包括

China

中国

,

，

Hong Kong

香港

,

，

Macau

澳门

and

和

Taiwan

台湾

) to develop and commercialize telitacicept, a novel dual-target fusion protein approved in

）开发和商业化telitacicept，一种新型双靶点融合蛋白获批在

China

中国

for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Under the terms of the agreement,

用于治疗全身性重症肌无力（gMG）、系统性红斑狼疮（SLE）和类风湿关节炎（RA）。根据协议条款，

Vor Bio

生物课前

will pay RemeGen an initial payment of

将向荣昌生物支付一笔初始款项

$125 million

1.25亿美元

consisting of an upfront payment of

包括一笔预付款

$45 million

4500万美元

as well as

以及

$80 million

8000万美元

of warrants to purchase common stock with an exercise price of

购买普通股的认股权证，行权价格为

$0.0001

0.0001元

per share. The agreement also provides for potential regulatory and commercial milestones exceeding

每股。该协议还规定了潜在的监管和商业里程碑超过

$4 billion

40亿美元

, in addition to tiered royalties.

，除了分层版税之外。

Vor Bio

生物之前

separately announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the 'PIPE') that is expected to result in gross proceeds of approximately

单独宣布已就私募公开发行股票融资（“PIPE”）达成证券购买协议，预计将带来约

$175 million

1.75亿美元

, before deducting expenses.

，在扣除费用之前。

Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE,

根据证券购买协议的条款，在PIPE交易结束时，

Vor Bio

生物课前

will issue prefunded warrants (the 'Warrants') to purchase an aggregate of 700,000,000 shares of common stock at a purchase price of

将发行预融资权证（“权证”），以购买总计7亿股普通股，购买价格为

$0.25

0.25美元

per Warrant.

每张认股权证。

Vor Bio

生物课前

intends to use the net proceeds from the PIPE to advance development of its clinical pipeline and for general corporate purposes. The PIPE is expected to close on

打算将PIPE的净收益用于推进其临床管道的开发和一般公司用途。PIPE预计将在

June 27, 2025

2025年6月27日

, subject to the satisfaction of customary closing conditions.

，须满足惯例的交割条件。

The Warrants have an exercise price of

认股权证的行使价格为

$0.0001

0.0001美元

per share and will become exercisable upon approval by

每股，并将在获得批准后可行权

Vor Bio

生物课前

stockholders of the issuance of the shares underlying the Warrants.

向股东发行认股权证所涉及的股份。

Vor Bio

生物课前

intends to hold a special stockholder meeting to approve, among other things, the issuance of the underlying shares.

打算召开特别股东大会，以批准（其中包括）相关股份的发行。

As of

截至

May 8, 2025

2025年5月8日

,

，

PureTech's

纯技术的

percentage ownership in

百分比所有权在

Vor Bio

生物课前

was approximately 2.1%, calculated on a beneficial ownership basis in accordance with

约为2.1%，根据以下规定按有益所有权基础计算：

SEC

证券交易委员会

rules.

规则。

The full text of the announcements from

公告的全文来自

Vor Bio

生物课前

are as follows:

如下所示：

Vor Bio Enters

生物进入之前

into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

与荣昌生物达成针对晚期自免管线的全球独家授权协议

Vor Bio

生物课前

receives ex-

收到 ex-

Greater China

大中华区

rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis

全球三期临床开发的新型双靶点重组融合蛋白telitacicept（治疗全身性重症肌无力）的开发和商业化权利

RemeGen receives initial payment of

荣昌生物收到首付款

$125 million

1.25亿美元

consisting of an upfront payment of

前期付款包括

$45 million

4500万美元

plus

加号

$80 million

8000万美元

of warrants, potential regulatory and commercial milestones exceeding

超过担保、潜在监管和商业里程碑的

$4 billion

40亿美元

, as well as tiered royalties

，以及分级版税

Seasoned biopharma leader,

资深生物制药领导者，

Jean-Paul Kress

让-保罗·克雷斯

, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical development, commercialization, and strategic growth

，医学博士，被任命为首席执行官兼董事会主席，拥有临床开发、商业化和战略增长的可靠业绩记录。

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

,

，

June 25, 2025

2025年6月25日

--

--

Vor Bio, Inc.

生物公司

(Nasdaq: VOR) and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) today announced entry into an exclusive license agreement granting Vor Bio global rights (excluding

(Nasdaq: VOR) 和荣昌生物制药（HKEX: 9995, SHA: 688331）今天宣布达成一项独家许可协议，授予Vor Bio全球权利（不包括

China

中国

,

，

Hong Kong

香港

,

，

Macau

澳门

and

和

Taiwan

台湾

) to develop and commercialize telitacicept, a novel dual-target fusion protein approved in

）开发和商业化telitacicept，一种新型双靶点融合蛋白获批在

China

中国

for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of

针对全身性重症肌无力 (gMG)、系统性红斑狼疮 (SLE) 和类风湿性关节炎 (RA)。根据协议条款，Vor Bio 将向荣昌生物支付首付款

$125 million

1.25亿美元

consisting of an upfront payment of

包括一笔预付款

$45 million

4500万美元

as well as

以及

$80 million

8000万美元

of warrants to purchase common stock with an exercise price of

购买普通股的认股权证，行权价格为

$0.0001

0.0001元

per share. The agreement also provides for potential regulatory and commercial milestones exceeding

每股。该协议还规定了潜在的监管和商业里程碑超出

$4 billion

40亿美元

, in addition to tiered royalties.

，除此之外，还有分层版税。

Telitacicept is a novel, investigational fusion protein that targets key immune pathways involved in autoimmune disease. By selectively inhibiting BlyS (also known as BAFF) and APRIL - cytokines critical to B cell survival - telitacicept reduces autoreactive B cells and autoantibody production. RemeGen is conducting a global Phase 3 clinical trial which is now enrolling in .

Telitacicept是一种新型的研究性融合蛋白，靶向参与自身免疫疾病的关键免疫通路。通过选择性抑制BlyS（也称为BAFF）和APRIL（对B细胞存活至关重要的细胞因子），telitacicept减少自体反应性B细胞和自身抗体的产生。荣昌生物正在进行一项全球III期临床试验，目前正招募患者。

the United States

美国

,

，

Europe

欧洲

, and

，以及

South America

南美洲

, with initial results expected in the first half of 2027.

，初步结果预计在2027年上半年出炉。

Vor Bio also announced that its Board of Directors (the 'Board') has appointed

Bio公司还宣布其董事会（“董事会”）已任命

Jean-Paul Kress

让-保罗·克雷斯

, M.D., as Chief Executive Officer and Chairman of the Board, effective today. This follows Dr.

，医学博士，自今日起担任首席执行官兼董事会主席。这是继

Robert Ang's

罗伯特·昂的

resignation from the positions of Chief Executive Officer and director earlier today.

今天早些时候辞去首席执行官和董事的职务。

Dr. Ang

安博士

will continue with Vor Bio as a strategic advisor to assist in the transition through

将继续担任Vor Bio的战略顾问，协助完成过渡。

October 2025

2025年10月

.

。

Dr. Kress's

克雷斯博士的

strategic vision and track record of transformative leadership position him to guide the company into its next phase of growth.

战略眼光和变革性领导的过往记录使他能够引导公司进入下一个增长阶段。

'I am absolutely thrilled to be leading Vor Bio as we transform the company to become a major player in autoimmune disease treatment,' said

“我非常激动能够领导Vor Bio，因为我们正在将公司转型为自身免疫性疾病治疗领域的主要参与者，”

Dr. Kress

克雷斯博士

, Chairman and Chief Executive Officer, Vor Bio. 'Targeting BAFF/APRIL signaling with telitacicept represents a significant advancement in addressing autoantibody driven diseases, which is highly differentiated from other modalities in this space. With a clinically advanced asset, we are uniquely positioned to develop this innovative therapy, with the goal of making a meaningful impact for patients living with autoimmune diseases around the world.'.

，董事长兼首席执行官，Vor Bio。 “使用泰利西普靶向BAFF/APRIL信号通路代表了在解决自身抗体驱动疾病方面的重大进展，这与其他在此领域的方法高度差异化。凭借临床上先进的资产，我们有独特的优势来开发这种创新疗法，目标是为全球患有自身免疫疾病的患者带来有意义的影响。”

Dr. Kress

克雷斯博士

brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of

在制药和生物技术行业拥有数十年的高管领导经验。他最近曾担任首席执行官一职。

MorphoSys

莫尔腓斯公司

, where he led the development, approval and commercialization of Monjuvi®️ (tafasitamab), and advanced the company's pipeline through the landmark acquisition of

，他在该公司领导了Monjuvi®（tafasitamab）的开发、审批和商业化，并通过具有里程碑意义的收购推进了公司的研发管线。

Constellation Pharmaceuticals

星座制药公司

in 2021, strengthening

2021年，加强

MorphoSys'

MorphoSys的

position in oncology innovation and ultimately leading to its subsequent acquisition by Novartis in 2024. Prior to that, he was CEO of

在肿瘤学创新领域的地位，最终导致其在2024年被诺华收购。在此之前，他曾担任

Syntimmune

Syntimmune

, guiding its lead immunology program through to acquisition by

，引导其主导的免疫学项目直至被收购

Alexion Pharmaceuticals

Alexion制药公司

. He currently serves on the Board of

。他目前在董事会任职

Sanofi S.A.

赛诺菲公司

and has held senior roles across leading biopharma companies.

并在领先的生物制药公司担任过高级职务。

'Today marks a transformative milestone for RemeGen and the global development of telitacicept,' said Dr.

“今天标志着荣昌生物和泰爱全球发展的一个转型里程碑，”博士说道。

Jianmin Fang

方建民

, CEO of RemeGen. 'The strategic out-licensing of telitacicept's ex-

，荣昌生物CEO。“泰爱®战略性的对外授权协议

China

中国

rights accelerates our mission to deliver this innovative therapy to patients worldwide and will help maximize telitacicept's clinical and commercial potential on the global scale.'

权利加速了我们将这种创新疗法带给全球患者的使命，并将有助于最大限度地发挥泰利西普在全球范围内的临床和商业潜力。

About Telitacicept

关于泰利西普

Telitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology.

Telitacicept是一种新型的研究性重组融合蛋白，旨在通过选择性抑制BLyS（BAFF）和APRIL（两种对B细胞和浆细胞存活至关重要的细胞因子）来治疗自身免疫疾病。这种双重靶向机制减少了自反应性B细胞和自身抗体的产生，这是自身免疫病理的关键驱动因素。

In a Phase 3 clinical trial in generalized myasthenia gravis in .

在 generalized myasthenia gravis 的第3期临床试验中。

China

中国

, telitacicept demonstrated a 4.8-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) vs. placebo at 24 weeks, the primary endpoint of the trial.

，telitacicept在24周时相较于安慰剂在MG-ADL（重症肌无力日常生活活动量表）上显示出4.8分的改善，这是试验的主要终点。

Telitacicept is approved in

泰利塔西普获批于

China

中国

for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across

针对系统性红斑狼疮（SLE）、类风湿关节炎（RA）和全身性重症肌无力（gMG）。目前，一项全球性的 gMG 三期临床试验正在各地进行。

the United States

美国

,

，

Europe

欧洲

, and

，以及

South America

南美洲

to support potential approval in

支持潜在的批准在

the United States

美国

and

和

Europe

欧洲

.

。

About Vor Bio

关于Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.

Vor Bio是一家临床阶段的生物技术公司，致力于改变自身免疫性疾病的治疗方法。该公司专注于快速推进telitacicept（一种新型双靶点融合蛋白）的3期临床开发和商业化，以应对全球严重的自身抗体驱动疾病。

For more information visit .

欲了解更多信息，请访问。

www.vorbio.com

www.vorbio.com

.

。

About RemeGen Co. Ltd.

关于荣昌生物有限公司

Founded in 2008, RemeGen is a leading biopharmaceutical company in

成立于2008年，荣昌生物是一家领先的生物制药公司

China

中国

committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices in

致力于为患有危及生命疾病的患者提供未满足临床需求的解决方案。荣昌生物在以下地点设有研究实验室和办公室：

China

中国

and

和

the United States

美国

. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases.

公司致力于在自身免疫性疾病、肿瘤学和眼科疾病等关键治疗领域，发现、开发和商业化具有显著临床价值的创新性和差异化生物药物。

# # #

# # #

Vor Bio Announces

Vor Bio 宣布

$175 Million

1.75亿美元

Private Placement

私募 placement

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

,

，

June 25, 2025

2025年6月25日

-- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the 'PIPE') that is expected to result in gross proceeds of approximately .

-- Vor Bio（纳斯达克代码：VOR），一家处于临床阶段的生物技术公司，致力于改变自身免疫性疾病的治疗方法，今天宣布已达成一项证券购买协议，进行私募公开股权投资（“PIPE”），预计将获得约 的总收益。

$175 million

1.75亿美元

, before deducting expenses.

，在扣除费用之前。

Private Placement

私募-placement

Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Vor Bio will issue prefunded warrants (the 'Warrants') to purchase an aggregate of 700,000,000 shares of common stock at a purchase price of

根据证券购买协议的条款，在PIPE交易完成时，Vor Bio将发行可预付认股权证（“权证”），以购买总计7亿股普通股，购买价格为

$0.25

0.25美元

per Warrant.

每张认股权证。

The PIPE included a syndicate of world-class investors including Vor Bio's existing stockholder

PIPE 包括一个由世界级投资者组成的财团，其中包括 Vor Bio 现有的股东。

RA Capital Management

RA资本管理

, as well as

，以及

Mingxin Capital

明信资本

, Forbion,

，Forbion，

Venrock Healthcare Capital Partners

Venrock 医疗资本合伙公司

,

，

Caligan Partners

卡利根合伙人

and NEXTBio.

和NEXTBio。

Vor Bio intends to use the net proceeds from the PIPE to advance development of its clinical pipeline and for general corporate purposes. The PIPE is expected to close on

Vor Bio 打算将来自 PIPE 的净收益用于推进其临床管线的开发以及一般公司用途。PIPE 预计将于

June 27, 2025

2025年6月27日

, subject to the satisfaction of customary closing conditions.

，需满足惯例的成交条件。

The Warrants have an exercise price of

认股权证的行使价格为

$0.0001

0.0001元

per share and will become exercisable upon approval by Vor Bio stockholders of the issuance of the shares underlying the Warrants. Vor Bio intends to hold a special stockholder meeting to approve, among other things, the issuance of the underlying shares.

每股，并将在Vor Bio股东批准发行与认股权证相关的股份后方可行使。Vor Bio计划召开特别股东大会，以批准包括相关股份的发行在内的若干事项。

​

​

The securities being issued and sold in the PIPE have not been registered under the Securities Act of 1933, as amended (the 'Securities Act').  Accordingly, these securities may not be offered or sold in

在私募股权投资（PIPE）中发行和出售的证券尚未根据修订后的《1933年证券法》（“证券法”）进行注册。因此，这些证券可能不得提供或出售于

the United States

美国

, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Concurrently with the execution of the securities purchase agreement, Vor Bio and the investors named therein entered into a registration rights agreement pursuant to which Vor Bio has agreed to file a registration statement with the .

，除非根据有效的登记声明或适用的《证券法》登记要求的豁免。同时，在执行证券购买协议时，Vor Bio 与其中指定的投资者签订了一份登记权协议，根据该协议，Vor Bio 已同意向 提交一份登记声明。

Securities and Exchange Commission

证券交易委员会

registering the resale of the shares of common stock issuable upon the exercise of the Warrants.

注册因行使认股权证而可发行的普通股股份的转售。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他司法管辖区进行这些证券的销售，因为在该等州或其他司法管辖区，此类要约、邀请或销售在根据任何该等州或其他司法管辖区的证券法进行注册或资格认定之前属违法。

About Vor Bio

关于Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.

Vor Bio是一家临床阶段的生物技术公司，致力于变革自身免疫性疾病的治疗方法。该公司专注于快速推进一种新型双靶点融合蛋白telitacicept的三期临床开发和商业化，以应对全球严重的自身抗体驱动疾病。

For more information visit .

欲了解更多信息，请访问。

www.vorbio.com

www.vorbio.com

.

。

# # #

# # #

About

关于

PureTech Health

纯科技健康

PureTech

纯技术

is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities.

是一家临床阶段的生物治疗公司，致力于为毁灭性疾病患者开发全新类别的药物以改变他们的生活。公司通过其经验丰富的研发团队以及广泛的科学家、临床医生和行业领袖网络，创建了一个广泛而深入的产品组合，这些产品正在通过内部及其创始实体共同推进。

.

。

PureTech's

PureTech的

R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the

研发引擎已促成29种治疗药物和候选药物的开发，其中三种已获得批准。

U.S. Food and Drug Administration

美国食品药品监督管理局

. A number of these programs are being advanced by

其中许多项目正在由

PureTech

纯技术

or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the

或其成立的实体在各种适应症和临床开发阶段，包括注册支持研究。所有导致这一治疗候选药物组合的底层项目和平台最初都是由其识别或发现，然后推进的。

PureTech

纯技术

team through key validation points.

团队通过关键验证点。

For more information, visit

欲了解更多信息，请访问

www.puretechhealth.com

www.puretechhealth.com

or connect with us on X (formerly Twitter) @puretechh.

或通过X（前身为Twitter）@puretechh与我们联系。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警告声明

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements,.

本新闻稿包含符合1995年《私人证券诉讼改革法案》定义的前瞻性陈述。本新闻稿中所有不涉及历史事实的陈述均应被视为前瞻性陈述。

including without limitation those related to

包括但不限于那些相关的

Vor Bio's plans for development and commercialization of telitacicept, the potential of telitacicept in various indications, the timing and pace of patient enrollment and dosing in clinical trials and the availability of data therefrom, the expected safety profile of telitacicept, the market opportunities for telitacicept, the ability of telitacicept to transform patient lives, Vor Bio's statements regarding the PIPE, including expected proceeds, expected use of proceeds and expected closing, expectations and timing with respect to a special stockholder meeting, and Vor Bio's and our future prospects, developments and strategies.

关于Vor Bio对telitacicept的开发和商业化计划，telitacicept在多种适应症中的潜力，临床试验中患者入组和给药的时间与进度及其数据的可用性，telitacicept预期的安全性特征，telitacicept的市场机会，telitacicept改变患者生活的能力，Vor Bio关于PIPE的声明，包括预期收益、预期用途及预期完成时间，关于特别股东大会的期望与时间安排，以及Vor Bio和我们的未来前景、发展和策略。

.

。

The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended .

前瞻性声明基于当前预期，且受已知和未知风险、不确定性以及其他可能导致实际结果、表现或成就与当前预期大相径庭的重要因素的影响，包括但不限于我们年度报告《20-F表格》中“风险因素”标题下所述的风险、不确定性和其他重要因素。

December 31, 2023

2023年12月31日

, filed with the

，提交给

SEC

证券交易委员会

and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release.

并包含在我们的其他监管文件中。这些前瞻性声明是基于公司当前和未来业务战略的假设以及公司未来运营的环境。每个前瞻性声明仅代表本新闻稿发布之日的情况。

Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise..

除非法律和监管要求另有规定，我们不承担更新或修改这些前瞻性陈述的义务，无论是否由于新信息、未来事件或其他原因。

Contact:

联系人：

PureTech

纯科技

Public Relations

公共关系

publicrelations@puretechhealth.com

公共关系@纯粹科技健康.com

Investor

投资者

Relations

关系

IR@puretechhealth.com

IR@puretechhealth.com

UK

英国

/EU Media

欧盟媒体

Ben Atwell

本·阿特威尔

,

，

Rob Winder

罗伯·温德

+44 (0) 20 3727 1000

+44 (0) 20 3727 1000

puretech@fticonsulting.com

puretech@fticonsulting.com

US Media

美国媒体

Justin Chen

陈智轩

+1 609 578 7230

+1 609 578 7230

justin@tenbridgecommunications.com

justin@tenbridgecommunications.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the

这部分信息由RNS的非监管新闻稿分发服务Reach提供，

London Stock Exchange

伦敦证券交易所

. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact

与此信息的使用和分发相关的条款和条件可能适用。欲了解更多信息，请联系

rns@lseg.com

rns@lseg.com

or visit

或访问

www.rns.com

www.rns.com

.

。

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the .

RNS可能会使用您的IP地址来确认您是否遵守了条款和条件，分析您如何与本通讯中包含的信息互动，并在我们的商业服务范围内以匿名方式与他人分享此类分析。欲了解有关RNS及更多信息，请点击。

London Stock Exchange

伦敦证券交易所

use the personal data you provide us, please see our

使用您提供给我们的个人数据，请参阅我们的

Privacy Policy

隐私政策

.

。

END

结束

NRAPPUAWQUPAUPQ

NRAPPUAWQUPAUPQ